Industry
Neurocrine to Buy Soleno for $2.9 Billion, Picks Up Prader‑Willi Drug VYKAT XR
Neurocrine will acquire Soleno for $2.9B to add VYKAT XR, the newly approved Prader‑Willi hyperphagia drug, aiming to expand its rare‑disease portfolio.